Related Experiment Video
Updated: Sep 15, 2025

14:27
Identification of Disease-related Spatial Covariance Patterns using Neuroimaging Data
Published on: June 26, 2013
15.8K
MesoSCOUT: A novel tool for revealing mesoscale organization in the white-matter connectome
Emil Dmitruk1, Christoph Metzner2,3, Volker Steuber1
1Biocomputation Research Group, Department of Computer Science, University of Hertfordshire, Hatfield, United Kingdom.
Biorxiv : the Preprint Server for Biology
|July 16, 2025
Summary
Researchers discovered distinct topological patterns in the brain
Area of Science:
- Neuroimaging and Computational Topology
- Brain Connectomics and Schizophrenia Research
Background:
- Schizophrenia (SCH) is a complex psychiatric disorder.
- Understanding alterations in brain connectivity is crucial for diagnosis and treatment.
- Current methods may not fully capture mesoscale connectome differences.
Purpose of the Study:
- To apply persistent homology (PH) via clique topology to analyze white-matter connectome differences.
- To identify and compare topological motifs between healthy controls (HC) and SCH subjects.
- To explore the generalizability of findings across different neuroimaging datasets (COBRE and HCP).
Main Methods:
- Utilized computational algebraic topology, specifically persistent homology (PH) with clique topology.
- Extracted and compared topological motifs from structural connectomes of HC and SCH groups.
- Validated findings using null models and examined cross-dataset structural overlap.
Main Results:
- Significant differences in topological motifs were found between HC and SCH groups.
- Identified shared mesoscale structures across two independent datasets (COBRE and HCP).
- Demonstrated the potential for cross-scanner comparability in connectome analysis.
Conclusions:
- PH via clique topology reveals novel mesoscale connectome differences in schizophrenia.
- This approach enables connectomic fingerprinting for potential neuroimaging-based diagnosis.
- Findings pave the way for developing targeted treatments for psychiatric and neurological conditions.

